Previous 10 | Next 10 |
Lenzilumab significantly improved the likelihood of survival without ventilation (SWOV) by 54% versus standard treatment in hospitalized patients with COVID-19 pneumonia IDWeek is the premier global scientific meeting that brings together infectious disease specialists from the In...
Humanigen plans to submit an MAA under the centralized procedure seeking Conditional Marketing Authorization (CMA) throughout the European Union (EU) for the use of lenzilumab to treat patients hospitalized with COVID-19 pneumonia Humanigen expects to request accelerated assessmen...
The following slide deck was published by Humanigen, Inc. in conjunction with this event. For further details see: Humanigen (HGEN) Presents At Global Healthcare Virtual Conference 2021 - Slideshow
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that management will present and participate at multiple virtual investor c...
Gainers: IVERIC (NASDAQ:ISEE) +62%. Echo (NASDAQ:ECHO) +53%. Endo International plc (NASDAQ:ENDP) +35%. Affirm (NASDAQ:AFRM) +32%. Elite Education (NASDAQ:EEIQ) +30%. SigmaTron (NASDAQ:SGMA) +25%. Onion Global (NYSE:OG) +21%. Farmmi (NASDAQ:FAMI) +20%. Aterian (NASDAQ:ATER) +19%. Camber Energ...
Shares of Humanigen (NASDAQ: HGEN) were sinking 15.6% lower as of 11:36 a.m. EDT on Friday. The decline came after the clinical-stage biopharmaceutical company announced on Thursday that the U.S. Food and Drug Administration turned down Emergency Use Authorization for lenzilumab in ...
Gainers: IVERIC bio (NASDAQ:ISEE) +56%, Endo (NASDAQ:ENDP) +46%, NGM Biopharmaceuticals (NASDAQ:NGM) +16%, Arbutus Biopharma (NASDAQ:ABUS) +15%, CareMax (NASDAQ:CMAX) +11%. Losers: Apellis Pharmaceuticals (NASDAQ:APLS) -50%, Mersana Therapeuti...
The bulls missed the mark on Thursday, with the major averages finishing the session comfortably in negative territory. Still, one niche sector hit a bullseye amid the general losses -- gun and ammunition manufacturers. The sector gained ground after the Biden administration backed down ...
Gainers: Gevo (NASDAQ:GEVO) +35%. American Virtual Cloud Technologies (NASDAQ:AVCT) +33%. Rocket Lab (NASDAQ:RKLB) +32%. Torrid (NYSE:CURV) +30%. Montauk (NASDAQ:MNTK) +25%. Impel (NASDAQ:IMPL) +22%. Gold Royalty (NYSE:GROY) +22%. ProQR (NASDAQ:PRQR) +21%. Hyzon (NASDAQ:HYZN) +21%. Rockley (N...
Humanigen (NASDAQ: HGEN) stock is sinking after the clinical-stage biopharmaceutical company shared devastating news. The FDA has declined Humanigen's request for emergency use authorization of lenzilumab, sending the biotech stock 52.1% lower as of 11:38 a.m. EDT on Thursday. ...
News, Short Squeeze, Breakout and More Instantly...
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...